Recent genome-wide association studies have identified hundreds of genetic loci as being associated with vascular diseases or traits and their risk factors. Many of the loci uncovered represent novel discoveries with no obvious candidate genes and molecular mechanisms, testifying to the complexity of vascular diseases. To understand the functional consequences of genetic variations and help pinpoint the underlying genes and mechanisms of common complex diseases, functional genomics that integrate genetic variations and intermediate molecular traits such as gene expression has been extensively studied in the past few years. This review summarizes the key concepts of functional genomics, the current state of the field, and its application in vascular diseases. (Arterioscler Thromb Vasc Biol. 2012;32:216-222.) Key Words: coronary artery disease Ⅲ coronary heart disease Ⅲ expression quantitative trait loci Ⅲ functional genomics Ⅲ genome-wide association study
V ascular diseases (VD), such as coronary artery disease (CAD), myocardial infarction, peripheral artery disease, and atherosclerotic carotid artery disease, and their risk factors, such as blood lipids and hypertension, are all common complex diseases or traits that involve complex interactions among multiple genetic variations and environmental factors. 1 The past 5 years have seen an explosion of genomewide association studies (GWAS) that simultaneously screen millions of genetic variations, primarily single-nucleotide polymorphisms (SNPs), in populations involving thousands to hundreds of thousands of individuals as an effort to understand the genetic architecture of common complex diseases. GWAS have enabled the discovery of hundreds of disease-associated genetic loci and provided unprecedented insights into the complexity of disease pathophysiology.
Based on the GWAS catalog 2 maintained by National Human Genome Research Institute, as of Nov. 10, 2011, 96 studies have been published on 40 VD-related diseases or traits, such as CAD, myocardial infarction, peripheral artery disease, stroke, aortic root size, carotid intima media thickness, abdominal aortic aneurysm, platelet traits, lipids, and hypertension (other VD risk factors, such as metabolic syndrome, diabetes, and smoking, are not included in this summary to keep the focus directly on VD). A total of 144 chromosomal regions and 315 distinct SNPs have been identified as being significantly associated with 1 or more VD-related diseases or traits studied, testifying to the great complexity of vascular diseases. For example, the most recent GWAS of more than 23 000 CAD cases and 65 000 controls identified 23 significant genetic loci, with 13 being novel and 17 presumably acting through mechanisms independent of traditional risk factors, such as lipids and hypertension. 3 Despite the success of GWAS in uncovering genetic loci modulating human diseases and traits, pinpointing the genes and mechanisms underlying the identified genetic loci is not a straightforward task. As pointed out in a review article by Manolio, 4 nearly 40% of disease/trait-associated SNPs are located in intergenic regions, and another 40% are intronic, whereas only 12% are located in or close to protein-coding regions of genes, and only Ͻ5% are nonsynonymous SNPs. 4 To nominate candidate genes, the commonly used strategy is to report the genes adjacent (typically within an arbitrarily defined distance, such as 500 kb) to the genetic loci, especially those with potential biological connections based on previous findings. This strategy yields uncertainty and little mechanistic insights. For loci in intergenic regions, no candidate genes are reported. Therefore, the inference for the functional and mechanistic connection between susceptibility loci and diseases/traits is more challenging than ever suspected.
In recent years, functional genomics studies of human populations have been conducted to infer functional consequences of genetic variations in human genome and to assist with candidate gene identification and mechanistic explanation of GWAS findings. This review discusses the key concepts behind functional genomics and examines its current state. The author also attempts to use the functional genomics resources compiled to date to highlight the utility and power of functional genomics in helping identify candi-date genes and mechanisms underlying GWAS loci for vascular diseases.
Key Concepts of Functional Genomics
Functional genomics studies the functional consequences of genetic variations on intermediate molecular traits such as gene expression, alternative splicing, and protein products. Two general approaches have evolved to tackle functional genomics. One approach relies on bioinformatics and computational predictions based on the locations and sequence properties of the DNA variation. Although useful, such predictions are speculative in nature, and experimental evidence is needed to support the predictions made. A more recent functional genomics approach focuses on experimental testing of the relationship between genetic variations and intermediate molecular traits to identify quantitative trait loci (QTLs). QTLs are genetic loci that are associated with changes in quantitative traits. QTLs of quantitative clinical traits or phenotypes, such as plasma lipid levels, are commonly referred as clinical QTLs. By treating intermediate molecular traits, such as transcription levels of genes and protein levels, as quantitative traits, intermediate QTLs (iQTLs) can be identified. The current review focuses on experimental iQTL studies but not the bioinformatics and computational approach because of the data-driven and hence presumably more accurate nature of iQTLs in predicting functional consequences of genetic variations.
The intermediate molecular traits under iQTL studies can range from gene-level traits, such as transcription levels of genes, alternative splicing, allelic expression, and gene product traits (such as protein levels or enzymatic activities), to epigenetic processes, such as microRNAs, DNA methylation, and histone modification. The study of genetic variations that are associated with gene transcript levels is termed genetics of gene expression, and the goal of this field is to identify expression QTLs (eQTLs) or expression SNPs by simultaneously screening for associations between millions of SNPs and tens of thousands of transcripts on human genome. Similarly, SNPs that are associated with other molecular traits, such as alternative splicing, allelic expression, enzyme activity, and methylation, can also be identified to predict the functions of the genetic variations.
The significant statistical association between a SNP and an intermediate molecular trait implicates the potential functional role of the SNP, although the associated SNP itself may not be causal or functional but simply in linkage disequilibrium with a true functional SNP. Based on the hypothesis that effects of genetic loci on clinical traits or phenotypes (ie, clinical QTLs) are mediated by intermediate molecular traits, the simultaneous association of a SNP with both an intermediate molecular trait (iQTL) and a particular clinical phenotypic trait (clinical QTL) can help identify candidate genes for the phenotype of interest. [5] [6] [7] [8] [9] [10] [11] [12] [13] In addition, the specific intermediate molecular traits that are associated with the GWAS SNPs can help inform the molecular pathways and mechanisms involved in the clinical traits as they provide information on whether the genetic loci affect transcription, protein products, epigenetic regulation, or other molecular processes.
Based on the relative chromosomal location between a genetic locus and the gene representing the correlated intermediate molecular trait, iQTLs can be divided into local or cis-iQTLs and distal or trans-iQTLs. 14 cis refers to regulation at or close to the structural gene. Examples of cis-iQTLs include genetic variations within the promoter region or a local enhancer/repressor that affect transcription factor binding and variations in the untranslated regions that affect mRNA stability, localization, and translational efficacy. trans indicates regulation at a distance. Examples of transregulatory elements are genetic variations within transcription factors and long range enhancers/repressors that control the transcription of the gene of interest. cis-and trans-iQTLs are generally loosely defined by an arbitrary chromosomal distance cutoff, such as 200 kb or 1 Mb, depending on individual studies. A cis-iQTL is defined as located within the defined distance to its associated gene and a trans-iQTL is located on different chromosomes or more than the distance cutoff from its associated gene if on the same chromosome.
Current State of iQTL Studies in Human Populations
The most extensively studied intermediate molecular trait to date is the transcription levels of genes through eQTL studies, which have been explored in various species including yeast, maize, mouse, rat, and human. 12, [15] [16] [17] The current review focuses on human eQTL studies. In human populations, various cell and tissue types, including lymphocytes, 18 lymphoblastoid cell lines, 18 -26 monocytes, 27 fibroblast, 28 T cells, 28 aortic endothelial cells, 29 whole blood, 30 liver, 30 -34 adipose tissues, 20, 25, 30, 31 stomach, 31 skin, 25 muscle, 30 brain, [35] [36] [37] osteoblasts, 38 and kidney, 39 have been subject to eQTL discovery. Most of the earlier eQTL studies focused mainly on immortalized lymphoblastoid cell lines and involved smaller sample sizes, typically on the scale of Ͻ100. More recent studies shifted to individual cell or tissue types that better represent physiological conditions in much larger cohorts. Table 1 summarizes the eQTL studies of cell/tissue types with VD relevance, including monocytes, lymphocytes, T cells, fibroblast, aortic endothelial cells, whole blood, liver, adipose, and kidney. As shown, the sample sizes for these eQTL studies range from Ϸ80 to Ͼ1000, and the majority are genome-wide scans of hundreds of thousands of SNPs against tens of thousands of genes or transcripts, yielding the identification of hundreds to thousands of eQTLs. So far majority of eQTLs identified fall within 100 kb of the gene and are thus cis in nature. 19, 22, 24 trans-eQTLs are intrinsically weaker and hence require a large sample size to achieve sufficient statistical power.
In addition to eQTLs, other types of QTLs, such as those for alternative splicing, 21,40 -43 allelic expression, 44, 45 long noncoding RNA, 21 DNA methylation, 46 -51 microRNA, 52 and liver enzyme activity, 53 have also been pursued. Compared with eQTLs, the study of these additional QTL types is less comprehensive, and fewer cell/tissue types have been explored. The current review focuses on eQTLs in subsequent sections.
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Comparison of eQTLs Across Cell/Tissue Types and Across Studies
One of the common observations among the eQTL studies is that both cross-tissue and cell/tissue-specific eQTLs exist. For instance, Dimas et al 28 reported that the percentages of eQTL overlaps across tissues are dependent on both sample size and similarity between tissues. With a sample size of Ϸ100, Ϸ30% of eQTLs overlap between liver and adipose, and 49% overlap between subcutaneous adipose and omental adipose. When the sample size increases to Ϸ800, the overlap increases to 60% between liver and adipose and 80% between the 2 adipose depots, suggesting that a relatively large proportion of eQTLs is shared between tissues. Some of the tissue-specific eQTLs could be a result of false discoveries. Therefore, reproducibility of eQTLs from the same cell/tissue type across studies is critical to select eQTLs of biological significance. Two of the common observations from studies analyzing consistency of eQTLs across studies are as follows: (1) strong cis-eQTLs tend to replicate, whereas trans-eQTLs are much less reproducible 21 ; and (2) eQTLs from studies with smaller sample sizes are less replicable. 54 Recently, Innocenti et al 33 investigated eQTLs in 
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Arterioscler Thromb Vasc Biol February 2012 3 independent liver cohorts and found that confounders that affect liver gene expression, such as drug exposure and clinical descriptors, and unknown factors all contribute to the ability to replicate eQTLs between studies. Some of unknown contributors may arise from less well-controlled tissue collection and handling procedures and hidden disease status, as in most cases of eQTL studies. Therefore, vigorous epidemiological considerations and thorough quality control are necessary to identify reliable signals.
Application of Functional Genomics Findings in Vascular Diseases
The power of using iQTLs, especially eQTLs or expression SNPs, to identify candidate causal genes and pathways has been demonstrated for a variety of diseases. 32, [55] [56] [57] For instance, using eQTLs from adipose tissue, Small et al 57 not only identified the transcription factor KLF14 as a master regulator underlying the 7q32.3 GWAS locus for type 2 diabetes and high-density lipoprotein cholesterol but also revealed a complex gene network that is regulated in trans by KLF14 for multiple metabolic phenotypes. As eQTLs from relevant tissues or cell types appear to be more informative for a particular disease or trait, 55 it is necessary to consider the tissue of origin when interpreting GWAS findings using eQTLs. For vascular diseases, eQTLs from blood, adipose, liver, aorta, heart, monocytes, macrophages, lymphocytes, smooth muscle cells, coronary artery endothelial cells, and aortic endothelial cells can be of particular interest.
As an effort to identify candidate causal genes for vascular diseases, all significant loci reported in GWAS catalog as of November 2011 were integrated with eQTLs from blood, adipose, liver, lymphocytes, and monocytes from 6 large eQTL studies 18,20,27,30 -32 (sample size Ͼ400) to identify candidate causal genes for VDs. The results for myocardial infarction and coronary heart disease are exemplified in Table  2 . For several loci, 1 candidate gene per locus was mapped based on eQTLs. These candidate genes include PCSK9, CDKN2B, LIPA, PDGFD, and UBE2Z. For other loci, the expression levels of multiple candidate genes are associated with each locus, with many candidate genes being mapped in a tissue-specific manner. For example, the 1p13 locus that was linked to CAD and low-density lipoprotein cholesterol are strongly associated with the expression of SORT1 in liver only, PSRC1 in multiple tissues, and CELSR2 in liver and adipose tissues. Among these, SORT1 has been recently experimentally confirmed to be the causal gene underlying this locus for both low-density lipoprotein and CAD via modulation of hepatic lipoprotein export. 58, 59 Interestingly, another candidate gene, PSRC1, is significantly associated with the same locus in liver, adipose, blood, and monocyte. It is therefore plausible to test whether PSRC1 also plays a role in CAD development via mechanisms other than lipid regulation in liver. For several intergenic GWAS loci where no genes are within 1 Mb distance, candidate trans-genes whose expression levels are associated with these loci could be mapped via eQTLs. The functional relevance of these candidate genes, especially the ones that are replicated in multiple tissues such as ULK3 and C9orf156, can be tested in additional experiments for potential mechanistic connections to vascular diseases.
Conclusions
Accompanying the rapid progress of GWAS of common complex diseases, functional genomics studies have also undergone dramatic transformation in the past few years from small cell line studies involving tens of samples to individual cell and tissue types involving hundreds to more than a thousand individuals, and from eQTL to iQTLs of many other types of intermediate molecular traits. Both common and tissue-specific eQTLs have been identified. The functional implication inferred from the functional genomics studies has been used to identify candidate causal gene underlying GWAS loci of common complex traits. By intersecting eQTL findings that link SNPs to the expression levels of genes with GWAS loci (clinical QTLs) of vascular diseases that associate SNPs with disease phenotypes or traits, both known and novel candidate causal genes are uncovered.
Future Directions
Despite extensive efforts from the current functional genomics studies, there is still much room to improve before a comprehensive map of genetic regulation of intermediate molecular traits can be derived and the power of functional genomics in assisting disease gene and mechanism discovery can be fully realized. First, to date, the majority of the studies have still been focused on eQTLs. Because genetic variations may exert their functional effects via mechanisms other than direct gene expression regulation, comprehensive multi-tissue scanning of other molecular iQTLs associated with traits such as microRNAs, proteomics, metabolites, histone modification, and chromatin structure is needed to further annotate the functional genome. For vascular diseases, improved coverage of cell/tissue types relevant to vascular diseases, such as macrophage, smooth muscle cells, and aorta, is needed. Second, the array-based genotyping platforms used in most functional genomics studies cover only common genetic polymorphisms and miss rare variants and structural variations, and the array-based gene expression measurements cover mainly known genes and transcripts, leading to sparse sampling of both genetic variations and transcripts and hence missing iQTLs. The problem is further exacerbated by the use of different platforms with different coverage in different studies, which is 1 of the reasons for poor replication across studies. Sequencing-based technologies can certainly address these concerns and become the gold standard for future functional genomics studies. 21, 60 Third, majority of the eQTLs identified with confidence thus far are cis in nature, whereas trans-eQTLs, although expected to be widespread, are more difficult to detect because of their smaller effect sizes. Recently, Fehrmann et al focused their attention on trans-eQTLs and were able to identify high-confidence trans-eQTLs across tissues. 30 Additional efforts and methodological development for trans-eQTL identification will certainly provide further insights into the molecular mechanisms of complex diseases. Last but not least, geneϫenvironment interaction, an important factor for complex diseases, has
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Functional Genomics for Vascular Diseases 219 been poorly studied in functional genomics. Thus far, only 1 study, by Romanoski et al, 29 has addressed geneϫenvironment interaction on eQTL identification in human aortic endothelial cells with and without challenges of proinflammatory oxidized phospholipids and confirmed the presence of geneϫenvironment QTLs. Future investigations in geneϫenvironment interaction, as well as iQTL discovery under various developmental, physiological, and pathological conditions, can certainly help further explain variations in complex traits.
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